A Small Molecule Discrimination Map of the Antibiotic Resistance Kinome  by Shakya, Tushar et al.
Chemistry & Biology
ArticleA Small Molecule Discrimination Map
of the Antibiotic Resistance Kinome
Tushar Shakya,1 Peter J. Stogios,2,3 Nicholas Waglechner,1 Elena Evdokimova,2,3 Linda Ejim,1 Jan E. Blanchard,4
Andrew G. McArthur,5 Alexei Savchenko,2,3 and Gerard D. Wright1,*
1M.G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University,
Hamilton, ON, L8S 3Z5, Canada
2Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON, M5G 1L6, Canada
3Center for Structural Genomics of Infectious Diseases (CSGID), Toronto, ON, M5G 1L6
4High-Throughput Screening Lab, Centre for Microbial Chemical Biology, McMaster University, Hamilton, ON, L8S 3Z5, Canada
5Andrew McArthur Consulting, Hamilton, ON L8S 3P6, Canada
*Correspondence: wrightge@mcmaster.ca
DOI 10.1016/j.chembiol.2011.10.018SUMMARY
Kinase-mediated resistance to antibiotics is a sig-
nificant clinical challenge. These enzymes share a
common protein fold characteristic of Ser/Thr/Tyr
protein kinases. We screened 14 antibiotic resis-
tance kinases against 80 chemically diverse protein
kinase inhibitors to map resistance kinase chemical
space. The screens identified molecules with both
broad and narrow inhibition profiles, proving that
protein kinase inhibitors offer privileged chemical
matter with the potential to block antibiotic resis-
tance. One example is the flavonol quercetin, which
inhibited a number of resistance kinases in vitro
and in vivo. This activity was rationalized by determi-
nation of the crystal structure of the aminoglycoside
kinase APH(2’’)-IVa in complex with quercetin and its
antibiotic substrate kanamycin. Our data demon-
strate that protein kinase inhibitors offer chemical
scaffolds that can block antibiotic resistance, pro-
viding leads for co-drug design.
INTRODUCTION
Resistance to antibiotics is a problem of global scope with
a massive impact on clinical treatment of infectious diseases
(Choffnes et al., 2010). The emergence of resistance to all
classes of currently used antibiotics and the accumulation of
multiple resistance mechanisms in individual pathogens has re-
sulted in strains impervious to all available drugs. This regression
toward the pre-antibiotic era continues unabated as efforts to
bring new antibiotics to market are diminishing (Cooper and
Shlaes, 2011; Gwynn et al., 2010). New drugs and antibiotic
strategies are urgently needed to fill this growing gap in infec-
tious disease control.
One of the challenges facing the drug discovery community is
the lack of new chemical scaffolds with antibiotic activity. This
has led to the open question of whether all easily implementable
antibiotic chemical scaffolds have already been exploited over
the last 50 years: the so-called ‘‘low hanging fruit’’ (Baltz, 2006;Chemistry & Biology 18, 1591–160Fischbach and Walsh, 2009). One option to meet the challenge
of new scaffold discovery is to expand antibiotic chemical space
using combinations of antibiotics and other bioactive com-
pounds (Ejim et al., 2011; Spitzer et al., 2011). A subset of this
strategy is to rescue ‘‘old’’ or orphaned antibiotics by inhibiting
the resistance-conferring enzymes (Kalan and Wright, 2011).
This has been highly effective in the b-lactam field, where
synthetic and natural product inhibitors of b-lactamases have
proven to be highly successful b-lactam antibiotic adjuvants
(Testero et al., 2010). Examples of such combinations in-
clude Augmentin (amoxicillin-clavulanate) (Leigh et al., 1981),
Zozysn (piperacillin-tazobactam) (Akova et al., 1990), and Una-
syn (ampillicin-sulbactam) (Labia et al., 1986). New combina-
tions continue to be actively pursued; for example, meropenem
and clavulanate have been recently shown to have potent
activity against Mycobacterium tuberculosis (Hugonnet et al.,
2009), and the novel b-lactamase inhibitor NXL104 (avibactam),
in combination with the cephalosporin ceftazidime, is active
against several Enterobacteriaceae harboring extended-spec-
trum b-lactamases and carbapenemases (Livermore et al.,
2008). The success of these combination therapies in combating
b-lactam resistance via b-lactamase inhibition suggests that the
same strategy could be applied to other resistancemechanisms.
Aminoglycosides and macrolides are clinically important antibi-
otics that are susceptible to inactivation by phosphorylation
catalyzed by drug modifying kinases and are thus amenable to
such an approach.
The antibiotic resistance kinome represents a set of enzymes
found at the cross-section of themicrobial kinome (Kannan et al.,
2007) and antibiotic resistome (Wright, 2007). This subset of
microbial kinases is prevalent both in clinical and environmental
isolates and confers resistance to several classes of antibiotics,
in particular the aminoglycosides (e.g., gentamicin, amikacin,
tobramycin, and streptomycin) and macrolides (e.g., erythro-
mycin, azithromycin, and telithromycin) (Wright and Thompson,
1999). These kinases show only modest primary sequence
similarity (pairwise sequence identities typically less than 35%)
forestalling accurate prediction of their specific activity and of
their substrate profile; however, structural analysis of several
members of this group demonstrate that they all adopt the
canonical Ser/Thr/Tyr protein kinase three-dimensional fold
(Fong et al., 2010; Hon et al., 1997; Nurizzo et al., 2003; Stogios
et al., 2011; Toth et al., 2010; Young et al., 2009). Furthermore,1, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1591
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phate transfer (Boehr et al., 2001b; Thompson et al., 2002) and
cryptic ability to phosphorylate peptides and proteins (Daigle
et al., 1999). The antibiotic binding site shows a higher degree
of structural dissimilarity than does the nucleotide-binding site,
the latter of which preserves an overall conserved architecture
and several conserved key catalytic residues. These observa-
tions suggest that kinase inhibitors, many of which target the
nucleotide-binding site yet are capable of remarkable specificity
(reviewed in refs. [Dar and Shokat, 2011; Liao, 2007]), have the
potential to also block antibiotic kinase (AK) activity. Indeed,
we have previously demonstrated the inhibition of the aminogly-
coside kinases APH(30)-IIIa and APH(2’’)-Ia by sulfonamide,
flavonoids, and the natural product wortmannin (Boehr et al.,
2001a; Daigle et al., 1997).
Human protein kinases are primary targets for the treatment of
cancer and have been extensively explored in drug discovery
(Knight et al., 2010; Zhang et al., 2009). To this end the pharma-
ceutical industry has significantly invested in the design and
synthesis of large libraries of compounds that target kinases.
These are an untapped resource of small molecule scaffolds
with the potential of blocking AK activity and through this over-
turning antibiotic resistance in bacteria. Testimony to the utility
of such libraries is the report that pyridopyrimidine kinase inhib-
itors have unanticipated antibiotic activity through the inhibition
of bacterial biotin carboxylase, a critical enzyme in fatty acid
biosynthesis (Miller et al., 2009).
Susceptibility to protein kinase inhibitors has been previously
tested using a high-throughput platform to quantitatively explore
the relationship among human protein kinases (Fabian et al.,
2005; Fedorov et al., 2007; Karaman et al., 2008). These efforts
provide a quantitative map of inhibitor-kinase space that can
inform drug discovery. This approach allows simultaneous eval-
uation of the spectrum of kinase activity among a panel of en-
zymes and facilitates selection of compounds based on down-
stream requirements as probes of biology or as drug leads.
Here we report a screen of a library of well-characterized kinase
inhibitors against a panel of fourteen AKs and show that these
inhibitors can be used to qualitatively and quantitatively dis-
criminate between different antibiotic resistance kinases. We
identified specific and general inhibitors of AKs, including pyri-
dopyrimidines for the selective inhibition of APH(30) enzymes
and flavonoids as general inhibitors of APH enzymes, and deter-
mined the crystal structure of an inhibitor-kinase pair. This
screening and structural analysis revealed AK active site features
that can be exploited in the identification of molecules that
reverse antibiotic resistance.
RESULTS
Functional and Phylogenetic Analyses of AKs
Antibiotic kinase enzymes vary in their antibiotic and nucleotide
triphosphate substrate specificities and regiospecific sites of
phosphorylation (Thompson et al., 1994). To ensure that this
diversity is adequately represented in our kinase inhibitor chem-
ical-genetic interaction study, we initiated a thorough analysis of
relatedness among AK sequences. Previously, such analyses
had been conducted using classical phylogenetic reconstruction
methods, such as neighbor joining (Thompson et al., 1994;1592 Chemistry & Biology 18, 1591–1601, December 23, 2011 ª2011Wright and Thompson 1999). This methodology is particularly
useful in phylogenetic analysis of high similarity sequences.
However, because of the significant sequence diversity among
AKs, especially in theC-terminal subdomain of the APH structure
(Stogios et al., 2011), this approach does not provide sufficient
rigor for classification of the diverse candidates for our analysis
of kinase inhibitor chemical-genetic interactions. We therefore
turned to a Bayesian analysis (Huelsenbeck and Ronquist,
2001; Scheeff and Bourne, 2005) to construct a statistically
robust tree of 34 AKs (Figure 1), whose antibiotic kinase activity
has been validated by either in vivo and/or in vitro activity. The
topology of this tree is consistent with empirically determined
enzyme functional data in that enzymes with similar phosphory-
lation site regiospecificity and/or antibiotic substrate specificity
grouped together in the same clade. Consistent with their broad
antibiotic specificity and distribution among many genera, the
APH(30) clade demonstrates the largest phylogenetic diversity.
This tree provided the basis for collection of a group of represen-
tative AKs to conduct the inhibitor screen.
We selected 14 AKs that represent the phylogenetic distribu-
tion, range of antibiotic specificity, source organism including
important pathogens, and localization of genes in the chromo-
some or in mobile genetic elements (Table S1 available online).
This subset of enzymes provides a broad cross-section of
currently known resistance kinase genetic space suitable for
our interrogation with protein kinase inhibitors. All fourteen
enzymes were expressed, purified and analyzed for antibiotic
substrate specificity and for nucleotide triphosphate selectivity
(Table S2).
Protein Kinase Inhibitor Screen of AKs
The14AKswerescreenedagainst theScreen-Well protein kinase
inhibitor library (http://www.enzolifesciences.com/BML-2832/
kinase-inhibitor-library/) to discover and assess chemo-selective
relationships across AKs. This library was chosen as it includes
broad kinase inhibitor chemical diversity and provides a tractable
number of compounds (80) for multiple enzyme screens. The
primary screens (Figure 2) were consistent with previous results
of similar screens conducted with a small number of kinase
inhibitors (Daigle et al., 1997), which provided the first evidence
that these compounds would serve as privileged scaffolds for
AK inhibition. Screens were conducted in duplicate and at two
compound concentrations (10 mM and 50 mM), facilitating valida-
tion by two-point dose response for inhibitor-AK pairs.
Our primary screen demonstrated that several compounds
(Figure 3), such as flavonoid natural products apigenin (1) and
quercetin (2) and the anthraquinone damnacanthal (3), possess
broad AK inhibitor activity. The screen also identified inhib-
itors with narrow specificity, such as the trisubstituted imid-
azole MAP kinase inhibitor SB-203580 (4) that only affected
APH(30)-Va and the isoquinoline sulfonamides H8 (5) and H9 (6)
that only inhibit APH(30)-IIIa.
In reciprocal analysis, we found that some AK enzymes, such
as APH(30)-Va from the neomycin producer Streptomyces
fradiae, were highly sensitive to many compounds. On the
other hand, the macrolide antibiotic kinases were conspicuously
unaffected by most of the inhibitors in this library, sug-
gesting these enzymes have significant structural differences
with APHs.Elsevier Ltd All rights reserved
Figure 1. Phylogenetic Analysis of Antibiotic Resistance Kinases
A phylogenetic analysis of 34 bona fide AKs, which have been grouped into six major groups: APH(2’’), orange; APH(30) and APH(3’’), yellow; APH(4) and APH(7’’),
green; APH(6), blue; APH(9), purple; MPH(20), red. Enzymes listed in bold were screened against the Screen-Well library, and those in red represent enzymes with
structural data. The evolutionary distances are to scale. A star (*) represents a branch point in which a polytomy was observed. See also Tables S1 and S2.
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compounds for further study based on the following criteria:
representative chemical scaffolds, range of specificity of the
inhibitors for AKs, and compound potency. Using this selection
criteria, 18 inhibitors were selected for follow-up studies (Fig-
ure 4): apigenin (1), quercetin (2), genistein (7), LY294002 (8), Tyr-
phostin 25 (9), Tyrphostin 47 (10), Tyrphostin AG1478 (11),
GW5074 (12), indirubin-30-monooxime (13), Ro-31-8220 (14),
olomoucine (15), PP1 (16), KN-93 (17), SB-202190 (18), BML-
259 (19), LFM-A13 (20), SP600125 (21), and ZM449829 (22).
The in vitro dose dependence (IC50) of these compounds was
first established. Compound-enzyme pairs that showed revers-
ible inhibition behavior (dose dependence, slope factor 1)
were further analyzed by determination of the Ki versus ATP
(or GTP) to provide a robust and quantitative measure of inhibitor
affinity (Table S3). The majority of inhibitors were competitive
with NTP with the exception of mixed inhibition behavior noted
for GW5074 (12) versus MPH(20)-Ia and MPH(20)-IIa; Ro-31-
8220 (14) versus APH(2’’)-IIIa and APH(30)-Ia; and ZM449829
(22) versus APH(4)-Ia and APH(9)-Ia. Ki values determined
for the selected inhibitor scaffolds varied over four orders ofChemistry & Biology 18, 1591–160magnitude, reflecting the significant diversity in their chemical
structure and their interactions with AK enzymes. These results
supported our hypothesis that protein kinase inhibitor com-
pounds are discriminating probes of antibiotic inactivating
enzymes and represent privileged chemical matter suitable for
inhibition of AKs.
Quantitative Analysis of AK Inhibition
The wide range in inhibitor affinity for AKs suggested that these
compounds could fingerprint specific AKs and associated fami-
lies. We therefore correlated inhibition data with AK phylogeny
by mapping the potency of each compound on the phylogenetic
tree (Figure 5) (Fabian et al., 2005). Inhibitors, such as quer-
cetin (2), Tyrphostin 47 (10), and GW5074 (12), showed broad
specificity across clades, whereas others, such as genistein
(7), PP1 (16), and Tyrphostin AG1478 (11), showed distinct clade
specificity.
Inhibitor-enzyme specificity varied significantly, even among
compounds with similar chemical scaffolds, paralleling analo-
gous studies with eukaryotic kinases (Fabian et al., 2005). For
example, four flavonoid natural products were surveyed in the1, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1593
Figure 2. Primary Screen of AK against
Protein Kinase Inhibitors
A 2D array of the 14 AKs against the 80 kinase
inhibitors tested from the Screen-Well kinase
inhibitor library. The average of the residual
activities, at both 10 mM and 50 mM, were plotted
and assigned a color based on the potency of
the inhibitor. Red denotes complete inhibition,
and black is no effect. The compounds have
been ordered based on relatedness by chemical
substructure.
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Figure 3. Screening Compounds 1
Chemical structures of screening compounds 1–6.
Figure 4. Screening Compounds 2
Chemical structures of screening compounds 7–22.
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Inhibition of Antibiotic Resistance Kinasesscreen: the flavone apigenin (1), the flavonol quercetin (2),
the isoflavone genistein (7), and the flavan-like chromone
LY294002 (8). These compounds are highly bioactive with well-
known antioxidant properties. Genistein (7), an inhibitor of the
Tyr kinase epidermal growth factor receptor (EGFR) (Traxler
et al., 1999), was the most selective flavonoid inhibitor of AKs
with activity versus APH(30)-Va, APH(3’’) Ia and, to a lesser
extent, APH(2’’)-IIIa but showed no activity against any other
APH. LY294002 (8), an inhibitor of phosphoinositide 3-kinases
(Vlahos et al., 1994), showed modest affinity for members
of the APH(30), APH(9), and APH(4) clades but was a potent
(2.4 mM) inhibitor of the streptomycin modifying enzyme
APH(3’’)-Ia. Similarly, apigenin (1), a regioisomer of genistein
(7), displayed enzyme selectivity analogous to LY294002 but
with improved affinity (sub mM Ki). On the other hand, quer-
cetin (2), which differs from apigenin (1) by the presence of
hydroxyl groups at position 3 of the C ring and at position 30 of
the B ring, was the most promiscuous inhibitor in the screen.
This compound targeted 12 of the 14 enzymes tested and was
active against all of the aminoglycoside kinases with affinities
spanning three orders of magnitude (Kis, ranging from 70 nM
[APH(30)-Va] to 25.1 mM [APH(2’’)-IVa]).
Several inhibitors demonstrated AK clade specificity. Both the
Src kinase inhibitor PP1 (16) (Hanke et al., 1996) and the EGFR
inhibitor Tyrphostin AG1478 (11) (Ward et al., 1994) were specific
for APH(30)-Ia, APH(30)-IVa and APH(3’’)-Ia. The Bruton’s tyrosine
kinase inhibitor LFM-A13 (20) (Mahajan et al., 1999) was only
active against representatives of the APH(2’’), APH(4), and
MPH(20) groups. Notably, all these enzymes are able to utilize
GTP, preferentially or in addition to ATP, as a phosphate donor.
LFM-A13 (20) also inhibited the APH(4)-Ia enzyme, which is
consistent with our structural analysis of this APH enzyme that
revealed significant active site similarity with APH(2’’)-IIa in the
nucleotide binding region (Stogios et al., 2011). The isoquinoline
sulfonamide KN-93 (17) also showed moderate activity against
two of the four APH(2’’) enzymes and both MPH(20) enzymes
tested, in addition to APH(30)-Ia and APH(30)-IIa.
Chemically related Tyr kinase inhibitors Tyrphostin-25 (9) and
Tyrphostin-47 (10) (Gazit et al., 1989) showed contrasting
effects against AK enzymes. Tyrphostin-47 (10) showed broaderChemistry & Biology 18, 1591–160AK inhibition, notably, in its affinity for APH(2’’) enzymes. With
both of these compounds containing the same benzylidenema-
lonitrile core, this difference in specificity may reflect the subtle
differences in their chemical composition, such as the absence
of the C2-OH or the presence of a thioamide group. Notably,
the Ki values for these compounds showed that they are com-
petitive inhibitors of ATP binding to AKs, in contrast with their
activity against protein tyrosine kinase targets in which they
have been shown to be competitive with the non-ATP substrate
by mimicking the target tyrosine residue (Gazit et al., 1989).
The remaining molecules showed little clade specificity.
However, SP600125 (21), indirubin-30-monooxime (13), olomou-
cine (15), and BML-259 (19) all share the ability to block APH(2’’)-
IIa, APH(4)-Ia, and APH(9)-Ia, suggesting active site structural
similarities that were not apparent from the phylogenetic
analysis.
Structure of the APH(2’’)-IVa-Quercetin Complex
To further understand the molecular mechanism behind the
broad inhibition of AKs by the flavonol quercetin (2), we deter-
mined the crystal structure of Enterococcal enzyme APH(2’’)-
IVa in apo form, as well as in complex with antibiotic substrate
kanamycin and in complex with both kanamycin and quercetin
(Figure 6). The latter crystal was obtained with the inhibitor
soaked into pre-grown co-crystals of enzyme with substrate.
The apo and kanamycin-bound structures were solved by the
single anomalous dispersion technique using Se-Met derivatized
protein, and this structure was used for determining the quer-
cetin-soaked structure bymolecular replacement (Supplemental
Experimental Procedures and Table S4).
The 3D structure of the protein shows the canonical APH fold
(Figure 4A) and closely resembled the structure of the apo form
of this enzyme reported by Toth et al. (form I; Toth et al., 2010)
with RMSD of 0.7 A˚ over 281 of the 299 residues. Quercetin1, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1595
Figure 5. Specificity Profiles of Kinase Inhibitors
versus AKs
The Ki of each compound was plotted against each
enzyme on the phylogenetic tree. The Kis are graphically
represented with a red circle to represent potency; the
larger the circle, the lower the associated Ki value; a small
blue circle denotes no inhibition. Complete quantitative
data can be found in Table S3.
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each nucleotide binding site of both APH(2’’)-IVa chains in the
asymmetric unit. Quercetin binding did not introduce any signif-
icant conformational changes compared to the apo or kana-
mycin-bound structures of this enzyme.
The quercetin molecule interacted with the hinge region of the
enzyme, partially mimicking interactions and the shape com-
plementarities between ATP and APH enzymes (Figure 4B).
Comparing the conformation of the inhibitor to that of ATP bound
to the closely related APH(2’’)-IIa structure (Young et al., 2009;
Figure S1), the central ring of the 3,5,7-trihydroxychromen-4-
one moiety of the inhibitor roughly superimposed with the
adenine moiety of ATP. The 5-OH and 4-ketone groups of quer-
cetin superimposed well with the N6 and N1 groups of the purine
ring; these groups all formed hydrogen bond interactions with
the hinge region of the enzyme. The 3-OH of quercetin formed
a hydrogen bond with the enzyme that mimics the weak
hydrogen bond between the C2-H atom of the purine ring of
ATP and the enzyme. The inhibitor also formed van der Waals
interactions with Ile44, Phe95, Leu204, and Ile216, residues
that are also involved in hydrophobic interactions with the
adenine ring of ATP. The A ring of quercetin extends into the
phosphate binding pocket, as the 7-OH formed hydrogen bonds1596 Chemistry & Biology 18, 1591–1601, December 23, 2011 ª2011 Elsevier Ltd All rto the side chains of Lys46 and Asp217, two
residues involved in contacting the phosphate
groups of ATP. The B ring of the inhibitor
accesses a region of the enzyme that ATP
does not and formed one hydrogen bond
between the 30-OH and the enzyme. The extent
of the enzyme-quercetin interaction network
and its Ki value compared favorably with the
extent of the enzyme-ATP interaction network
and its Km value (six compared to four hydrogen
bonds and 25.1 mM compared to 11.3 mM for
quercetin and ATP, respectively). The broad
spectrum of inhibition of APH enzymes by quer-
cetin could be rationalized by the observation
that most of the interactions observed involved
backbone residues and amino acid side chains
that are universally conserved across all APH




Based on the obtained structural and inhibition
data, a structure-activity relationship analysis
was conducted to identify the determinants of
flavonoid binding to APH(2’’)-IVa. A spectrum
of molecules was surveyed to explore flavonoid chemical
space, including flavans ((+)-catechin, (±)-naringenin), flavones
(apigenin, baicalein, and luteolin), flavonols (3-hydroxyflavone,
kaempferol, quercetin, morin, and myricetin), and the isoflavone
genistein (Table S5).
The most potent inhibitory activity against APH(2’’)-IVa was
seen with the flavonols. Myricetin showed activity against
APH(2’’)-IVa compared to that of quercetin. Myricetin differs
from quercetin by an additional hydroxyl group attached to
the C50 of the B ring. Based on our structure of APH(2’’)-IVa,
this additional group would not make interactions with the
enzyme, and therefore the similar inhibition potency was
expected.
Luteolin was the only flavone to show activity against APH(2’’)-
IVa. This compound is also highly similar to quercetin, differing
only in the absence of a hydroxyl on C3. In the crystal structure
of APH(2’’)-IVa in complex with quercetin, this hydroxyl formed
an interaction with the backbone carbonyl of Ile98 (interaction
E in Figure 4C); consequently the absence of this group in luteolin
results a 3-fold drop in Ki. Similarly, the flavonol kaempferol is
highly similar to quercetin but lacks the hydroxyl on C30, which
interacts with the backbone carbonyl of Gly100 (interaction













































Figure 6. Crystal Structure of the APH(2’’)-IVa-
Kanamycin-Quercetin Complex
(A) Structure of the APH(2’’)-IVa-kanamycin-quercetin
complex, showing one of the two complexes in the
asymmetric unit.
(B) Quercetin molecules bound to chain A of APH(2’’)-IVa,
showing simulated annealing omit Fo-Fc density at 1.0s
(green). Side chains forming interactions with the inhibitor
are labeled and hydrogen bonds are indicatedwith dashed
red lines.
(C) Mapping of interactions between quercetin and
APH(2’’)-IVa. Interaction sites in which the distance
between the flavonoid and APH enzyme are within 4 A˚ are
labeled with letters A through J, with H-bonds indicated by
dashed black lines, and van der Waals interactions
indicated by red fans. Also see Figures S1 and S3; Tables
S4 and S5.
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lacking both the C3 and C30 hydroxyls, showed no affinity
against APH(2’’)-IVa (highest concentration tested 50 mM), indi-
cating the importance of at least one of interactions D or E.
Morin, on the other hand, is a structural isomer of quercetin
and might be expected to have similar binding kinetics to that
of kaempferol. However, the swap of the hydroxyl from C30 to
C20 resulted in a complete loss in inhibitory activity; it is possible
that the C20 hydroxyl produced a steric hindrance with the
enzyme as the B ring would adopt a flipped orientation, playing
the C20 hydroxyl 3.3 A˚ from the Cg1 group of Ile216. Finally,
the flavone baicalein had no activity against APH(2’’)-IVa, consis-
tent with the absence of functional groups to take part in the
essential contacts D and E. In addition, baicalein has a hydroxyl
moiety on C6, which may have produced a steric clash with the
Phe95 (interaction A).Chemistry & Biology 18, 1591–1601, December 23,The lack of inhibition of APH(2’’)-IVa by apige-
nin was unexpected because the closest struc-
tural homolog of this enzyme, APH(2’’)-IIa,
showed a high level of sensitivity to this flavone.
Superposition of the 3D structures of APH(2’’)-
IVa and APH(2’’)-IIa revealed that Arg92 in
APH(2’’)-IIa, which corresponds to Pro102 in
APH(2’’)-IVa, could be capable of forming an
interaction ‘‘G’’ with the C40-OH of apigenin.
The lack of interactions D and E in apigenin
could be compensated by the presence of inter-
action G with the C40-OH in APH(2’’)-IIa.
Of the remaining flavonoids, none of the
flavans (catechin and naringenin) showed any
activity against APH(2’’)-IVa. This indicates that
the carbonyl on C4 absent in these compounds
is essential to flavonoid binding to this enzyme.
In addition, the presence of a chiral center at C2
in naringenin may have created an unfavorable
conformation of the flavonoid, disallowing bind-
ing in the hinge region. 3-hydroxyflavone also
did not inhibit this enzyme; it contains the
4-carbonyl oxygen but lacks the C5 and C7
hydroxyls, suggesting one or both of interac-
tions B and J were critical for inhibition.The isoflavone genistein also showed no interaction against
APH(2’’)-IVa, which is likely due to the positioning of ring B at
C3 versus C2 as seen in quercetin. The 30-hydroxyphenyl ring
at this position would sterically interfere with the hinge region
of the enzyme.
Impact of Kinase Inhibitors on Antibiotic Resistance
The protein kinase inhibitors identified in these screens having
in vitro inhibitory activity against AKs were examined for their
ability to attenuate resistance in vivo of bacteria harboring resis-
tance genes. While several compounds were highly bioactive
and significantly reduced the activity of resistance elements,
none of the inhibitors was sufficiently potent to completely block
resistance. To quantify this intermediate bioactivity, we devel-
oped a measure that we term the antibiotic rescue factor (ARF;
Supplemental Experimental Procedures and Figure S2). The2011 ª2011 Elsevier Ltd All rights reserved 1597
Table 1. Antibiotic Rescue Factors
Antibiotic Resistance Enzyme Antibiotic MIC (mg/mL) Kinase inhibitor Ki (mM) ARF
1
APH(2’’)-Ia Kanamycin A 128 Quercetin 25 0.45
APH(2’’)-IVa Kanamycin A 128 Quercetin 25 0.10
APH(30)-Ia Kanamycin A 512 Apigenin 5.3 0.49
APH(30)-Ia Kanamycin A 512 Quercetin 1 0.19
APH(30)-IIa Kanamycin A 256 Quercetin 8.1 0.12
APH(30)-IIIa Kanamycin A 128 Quercetin 24 0.30
APH(30)-Va Neomycin 32 Apigenin 0.18 0.30
APH(30)-Va Neomycin 32 Quercetin 0.07 0.05
APH(30)-Va Neomycin 32 Genistein 21 0.25
APH(4)-Ia Hygromycin B 512 Apigenin 0.86 0.09
APH(4)-Ia Hygromycin B 512 Quercetin 1.2 0.17
APH(9)-Ia Spectinomycin 64 Apigenin 5.9 0.56
APH(9)-Ia Spectinomycin 64 Quercetin 0.56 0.01
1-ARF was calculated with antibiotics at one-fourth MIC and kinase inhibitor at 5xKi following 16 hr of growth at 37
C. See also Figure S2.
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itory concentration (MIC) at an inhibitor concentration equal to
5x the in vitro Ki. The ARF is a normalized value that indicated
the increase in cell death resulting from the combination of
the inhibitor and the antibiotic in the presence of a resistance
enzyme; a value of 0 indicates no effect while a positive number
reflects inhibition of the resistance mechanism. We explored
the ARF values with the flavonoids quercetin, apigenin, and
genistein against a representative panel of APHs (Table 1). In
several cases a positive ARF value was measured, cor-
relating well with Ki and demonstrating that protein kinase
inhibitors can suppress the activity of antibiotic resistance
enzymes.
DISCUSSION
The global spread of antibiotic resistance has created an urgent
need for novel antimicrobial therapies. There is significant con-
cern that identifying novel chemical scaffolds suitable for new
antibiotics will be extremely challenging. This notion is in line
with only a few examples of truly novel compounds recently
approved for use or in late-stage clinical trials. It is therefore
imperative to investigate novel ways to re-deploy known antibi-
otics in a fashion that minimizes resistance. One approach to
extend the efficacy of existing antibiotics is their co-administra-
tion with inhibitors of resistance elements, a clinically proven
method to overcome b-lactam antibiotic resistance caused by
b-lactamases (Kalan and Wright, 2011). Antibiotic kinases are
another suitable target for such inhibitors as they are common
sources of resistance to aminoglycoside and, to a lesser ex-
tent, macrolide antibiotics in pathogens. As well, they share
elements of protein structure, including a ‘‘druggable’’ active
site and mechanism that could be targeted by small molecules.
The link between AKs and Ser/Thr/Tyr protein kinases (Daigle
et al., 1999; Hon et al., 1997) offers an opportunity to repur-
pose protein kinase inhibitors as leads for molecules that
block AKs.
The relationship between AKs and protein kinases was ex-
ploited to establish a quantitative small molecule-AK interaction1598 Chemistry & Biology 18, 1591–1601, December 23, 2011 ª2011map using a library of structurally diverse and well-characterized
protein kinase inhibitors. This analysis confirmed that these
molecules are suitable for AK inhibition and identified both highly
promiscuous (e.g., quercetin) and clade-specific inhibitors. Ex-
amples of the later included LFM A13, which targets the GTP-
utilizing APH(2’’) and MPH enzymes, and PP1 and AG1478 that
primarily inhibit APH(30) enzymes.
An ideal AK inhibitor would efficiently block the activity of most
AKs and in our screen; the flavonol quercetin was the best
candidate, inhibiting all of the tested APHs (but not MPHs).
This flavonol blocked antibiotic modification by all of the twelve
tested APH with Ki values spanning four orders of magnitude.
Flavonoids are ubiquitous in nature and have been sourced
from a number of plants, including grasses, trees, fruits, and
vegetables. They are among the active agents inmany traditional
medicines and are known for their antioxidative (Woodman and
Chan, 2004), antihypertensive (Perez-Vizcaino et al., 2009), anti-
cancer (Teillet et al., 2008), and antimicrobial properties (Cushnie
and Lamb, 2011). Quercetin and its glycoconjugates are widely
distributed in plants and well tolerated in humans (Bischoff,
2008; Kelly, 2011).
We determined the crystal structure of APH(2’’)-IVa in com-
plex with its substrate kanamycin and the inhibitor quercetin. It
revealed several key contacts required for quercetin binding to
the APH(2’’)-IVa active site and allowed rationalization of inhibi-
tory action of other flavonoid molecules. Quercetin occupied
the ATP binding site and interacted with the enzyme through
a series of hydrogen bonds, involving hydroxyls 3,5,7, and 30,
plus the ketone on position 4 (interactions D, B, I-J, E, and C in
Figure 4C). The importance of the C30-OH group was inferred
from the 4-fold increase in Ki with the 3-deoxy-analog kaemp-
ferol. Analogues lacking 3, 5, or 7 hydroxyls are either weak or
noninhibitory against APH(2’’)-IVa (Table S5). Notably, apigenin
(lacking hydroxyls at position 3 and 30 and therefore unable to
make contacts D and E) did not affect APH(2’’)-IVa but did inhibit
the closely related enzyme APH(2’’)-IIa. A structural comparison
(Figure S3) between APH(2’’)-IIa and APH(2’’)-IVa enzymes
revealed that APH(2’’)-IIa may form a novel contact G between
the C40-OH and Arg-92, which could override the necessity ofElsevier Ltd All rights reserved
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quercetin is a bona fide inhibitor of AKs, and the inhibition
observed by quercetin is not the result of the formation
of nonspecific aggregates as demonstrated by other studies
(McGovern and Shoichet, 2003).
We observed that several compounds partially blocked resis-
tance enzyme activity in vivo as evidenced by increased antibi-
otic potency by decrease of culture survival of drug-resistant
bacteria. Unlike the precedent setting co-drug inhibitors of
b-lactamases, none of the resistance kinase inhibitors identified
in this study irreversibly blocked enzyme activity. Rather, all
were reversible inhibitors with no evidence of slow onset or
tight binding inhibition that is characteristic of highly potent
in vivo activity, perhaps due to the fact that these compounds
were not optimized and/or selected from a commercial library
designed to target eukaryotic kinases. To take this reversible
incomplete inhibition into account, we established a quantitative
measure of this activity in the form of an antibiotic rescue factor
(ARF). Using the ARF measure, quercetin was shown to be
significantly bioactive against isolates expressing a number of
aminoglycoside resistance kinases. This demonstrated that
kinase inhibitors in general, and the flavanoid scaffold in
particular, can be used successfully as lead molecules to
potentiate antibiotics in resistant bacteria. Further optimization
of the identified scaffolds is warranted in order to improve their
efficacy.
In this study we have developed a quantitative interaction map
of antibiotic kinase genetic and protein kinase inhibitor space.
This work unequivocally demonstrated that these compounds
represent privileged chemical matter with affinity for antibiotic
resistance kinases that can also potentiate antibiotics in vivo.
In an era of increasing antibiotic resistance and a commensurate
clinical need for new anti-infective agents, inhibiting resistance
to rescue our existing arsenal of drugs is an attractive strategy.
Given significant advancement in composition of diverse librar-
ies of kinase inhibitors and in their optimization currently present
in industrial and academic laboratories, this work opens a new
application for these compounds by harnessing their potential
as antibiotic co-drugs.
SIGNIFICANCE
Antibiotic resistance kinases reduce the efficacy of amino-
glycoside and macrolide antibiotics and are a growing pro-
blem in the successful management of bacterial infections.
These resistance kinases share structure, mechanism, and
function with protein kinases that are prized targets for
medicines in many human diseases. We screened a chemi-
cally diverse library of protein kinases against a panel of 14
resistance kinases that sample the broad genetic diversity
of these enzymes in the clinic and the environment. We
showed that protein kinase inhibitors offer privileged scaf-
folds with affinity for resistance kinases. This work conclu-
sively shows that the repurposing of chemical libraries
well developed in pharma for campaigns in cancer and other
diseases, involving protein kinases, can identify molecules
with orthogonal ability to inhibit antibiotic resistance ki-
nases. Such compounds could be formulated as co-drugs
to overcome antibiotic resistance.Chemistry & Biology 18, 1591–160EXPERIMENTAL PROCEDURES
Pyruvate Kinase/Lactate Dehydrogenase Coupled Enzyme Assay
The phosphorylation of antibiotics was monitored by coupling the release of
ADP or GDP with pyruvate kinase/lactate dehydrogenase (PK/LDH; Pon and
Bondar, 1967). The oxidization of NADH (ε = 6220 M-1 cm-1) was monitored
at 340 nm using a SpectraMax Plus384 microtiter plate reader in a 96-well
format. A typical reaction contained 250 ml of reaction contained 50 mM
HEPES (pH 7.5), 40 mM KCl, 10 mMMgCl2, 0.3 mM NADH, 3.5 mM phophoe-
nolpyruvate, 0.00125 units PK/LDH, 1% DMSO (v/v), antibiotic kinase, antibi-
otic substrate, and nucleotide. The reaction was allowed to incubate for 5 min
at room temperature in the absence of nucleotide and subsequently initiated
with nucleotide and monitored for 5 min at 340 nm.
Initial rates were determined by utilizing the linear portion of the progress








Kinase Inhibitor Screening Conditions
The assay conditions described previously were scaled down 100 ml to accom-
modate 384-well plate screening; the nucleotide concentration was held at
a concentration equal to the Km, antibiotic concentration was kept at 2–10
times Km, and the amount of enzyme added was determined empirically
such that the reaction was in the linear range for 10 min at the fixed drug
and nucleotide concentration (Table S2). Reagent transfers to assay plates
were made with a Biomek FX liquid handler (Beckman Coulter Inc., Fullerton,
CA). A Z0-score (Zhang et al., 1999) was determined for each of the screening
conditions, with the high and low controls, where the low control is an absence







A Z0-score greater than 0.5 was considered acceptable for screening
purposes. A summary of the Z0-score data and screening conditions is found
in Table S2. The screen was conducted in duplicate at two concentrations
(10 mM and 50 mM) of kinase inhibitor from the Screen-Well Kinase Inhibitor
library (version 2.1; Enzo Life Sciences/BIOMOL; Figure 1). Hits were assessed
by residual activity, which is calculated by Equation 4, where v is the velocity of




  100: (4)
Inhibition Kinetics
A secondary analysis was conducted on hits by assessing the IC50 of each
compound against each enzyme (data not shown). If the IC50 showed dose-
response against the activity of the enzyme, a Ki against ATP was conducted
in triplicate. The Ki data were fit to multiple models of reversible enzyme inhi-
bition and best fit assessed by chi-square values and F-test comparisons in
GraFit 4.0.21 (Erithacus Software).
Phylogenetic Analysis of AKs
A preliminary alignment of 34 AKs (see Supplemental Experimental Proce-
dures) was produced using the phosphotransferase enzyme model from
Pfam (Pf01636, Pfam database at theWelcome Trust Sanger Institute) in order
to align all of the core APH motifs with HMMER 3.0 (Eddy, 2009) using default
parameters. It was followed by five rounds of refinement with MUSCLE v3.7
(Edgar, 2004) and manual adjustment of APH(4)-Ia, APH(6)-Id, and APH(9)-Ia
to ensure alignment in the conserved regions.
The tree was estimated with two runs of 5 million generations of a
Metropolis-coupled Markov chain Monte Carlo (MCMCMC) algorithm (Altekar1, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1599
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Inhibition of Antibiotic Resistance Kinaseset al., 2004) with four chains per run inMrBayes (v3.1.2; Ronquist and Huelsen-
beck, 2003) using a gamma model of among-site variation and estimating
a proportion of invariant sites. A fixed Whelan and Goldman (WAG) model
was used after previous runs with mixed substitution models converged to
100% posterior probability for WAG (Whelan and Goldman, 2001). Random
topology trees were sampled every 100 generations. The most probable tree
and associated posterior probabilities were determined using a burn-in of
1,000 sampled generations using the 50% majority rule.
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